Skip to content

Low dose muscle relaxant in intubation in children

Low dose muscle relaxant in intubation in children

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-005207-15-SE
Enrollment
64
Registered
2004-12-28
Start date
Unknown
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: Esmeron Product Name: rocuronium bromide Product Code: Esmeron Pharmaceutical Form: Injection* Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Intrav

Sponsors

Region Skåne
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Children, 1 month to 12 years, admitted for surgery at our hospital. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Suspected difficult intubation. Increased risk of regurtation and aspiration.

Design outcomes

Primary

MeasureTime frame
Main Objective: Intravenous induction of an anaesthesia to a child is an established method in our department. Certain procedures requires tracheal intubation after administration of a muscle relaxant. If you want to avoid succinylcholine with its potential side effects you have non depolarizing blocking agents with a duration of action that may be too long in relation to the length of the procedure. The main objective of this study is to see whether adding a low dose muscle relaxant (rocuronium) to propofol and remifentanil would improve the intubating condition in children.;Secondary Objective: ;Primary end point(s): Will adding a low dose of rocuronium improve intubating conditions after induction with propofol and remifentanil.

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026